surmount tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial The SURMOUNT-MAINTAIN Phase 3b trial

Lose 13.6% of your body weight on average. One daily tablet = comparable results to injectable Wegovy. Eligible patients lost an average of 13.6% of their body weight in a 64-week clinical trial evaluating 25 mg oral semaglutide compared to those on 2.4 mg injectable semaglutide who lost an average of 14.9% of their body weight in a 68-week clinical trial

This may reflect the absence of effect of DPP-4 on GE or the higher circulating concentrations of GLP-1 observed in PAM carriers may augment the effect of DPP-4i in prolonging the half-life of GLP-1, which may off set the expected GLP-1 resistance [55]

Retatrutide weight-loss shot should only be used under medical care

We set realistic expectations with our patients from the start